NEW YORK, Jan. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
IntroductionPharma is facing slowing sales growth in the developed pharmaceutical markets, driven by increasing generic competition. However, the speed and severity of brand erosion is by no means equal across countries, prescribing setting, therapy area and formulation type; factors which are of key importance when managing and forecasting branded drug sales.
Features and benefits* Analyzes brand erosion (in terms of volume and value) in the US, Japan, France, Germany, Italy, Spain, UK, Australia China and Russia* Assesses brand erosion across the two major prescribing settings (retail and hospital)* Examines brand erosion across the various different therapy areas* Analyzes brand erosion according to drug formulation (oral, oral long lasting, parenteral and other formulation types)
HighlightsBrands tended not to experience generic erosion in China following patent expiry since they often face generic competition from the outset, and instead continue to grow both in terms of volume and value. Brand erosion was greater in terms of speed and severity in the hospital setting most likely reflecting the greater brand loyalty among patients in the retail setting. In terms of erosion by therapy areas, sales and volume erosion was the greatest among infectious disease, oncology, and cardiovascular small molecule brands.
Your key questions answered* Evaluate the evolving prescription pharmaceutical landscape and how this is being impacted by generics* Quantify sales and volume erosion across 10 major pharmaceutical markets according to prescribing setting, therapy areas, and drug formulation* Assess drivers and resistors for the uptake of generic drugs in each market
Copyright©2010 PR Newswire.
All rights reserved